title: Aescin: microcirculatory activity. Effects of accessory components on clinical and microcirculatory efficacy.
abstract: OBJECTIVE
  This study was performed to test the hypothesis that the heparin and phosphatidylcholine (PDC) included in Aescin gel formulations had the main role of allowing a better penetration of Aescin without important pharmacodynamic effects. Heparin and PDC should be considered as "enhancers". They do not have - at the dosage used - a specific or independent action. An open, registry study of patients - a group with chronic venous insufficiency (CVI) and a group of patients with diabetic microangiopathy were completed.
  
  
  METHODS
  In patients with CVI and in patients with diabetic microangiopathy, we used a commercial gel preparation containing Aescin, PDC and heparin (group A). The first group of patients used the full complex. The second group used the complex without PDC (group B) and the third (group C) used the complex without heparin.
  
  
  RESULTS
  In both studies the different groups of patients were comparable. In CVI patients (mean age 44.5; SD 2.4; range 40-50) venous microangiopathy was present at the perimalleolar region. Aescin produced comparable microcirculatory results with and without the two other components. Transcutaneus PO2 [TcPO2] increased in all groups. Transcutaneus PCO2 (TcCO2) decreases. The increased Laser Doppler Flux (LDF) (typical of CVI) decreased towards normality. The local Plasma Free Radicals [PFR] levels decreased as the result of better skin perfusion (P<0.05). Comparable data were observed in subjects with diabetic microangiopathy (mean age 46.5; SD 3.1). In these patients the compound was applied at the dorsum of the foot. TcPO2 increased with treatment. TcPCO2, skin flux and PFR decreased towards normal levels (P<0.05).
  
  
  CONCLUSIONS
  In conclusion Aescin improves the microcirculation and PFR. Heparin and PDC - included in the gel - have an ancillary role. An improved perfusion and nutrition of the skin was observed both in diabetic and venous microangiopathy. This may possibly contribute in the reduction of the incidence of ulceration associated with diabetic and venous microangiopathy. Aescin-based products may be included in a more complex management plan, including several systemic and local treatments.
authors: Irvine3 Labs, Department of Biomedical Sciences, Chieti - Pescara University, Pescara, Italy.
authors: R
authors: R
authors: Luzzi
authors: B
authors: B
authors: Feragalli
authors: G
authors: G
authors: Belcaro
authors: M R
authors: MR
authors: Cesarone
authors: U
authors: U
authors: Cornelli
authors: M
authors: M
authors: Dugall
authors: M
authors: M
authors: Hosoi
mesh_terms: D000287:Administration, Topical; D000328:Adult; D002317:Cardiovascular Agents / Q000008:administration & dosage; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000503:physiopathology; D004928:Escin / Q000008:administration & dosage*; D005260:Female; D005782:Gels; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000187:drug effects*; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000008:administration & dosage; D012042:Registries; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D002317:Cardiovascular Agents; D005782:Gels; D010713:Phosphatidylcholines; D004928:Escin; D006493:Heparin